Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

Table 6 Pharmacokinetic parameters

	C_max/D	T_max	AUC0_0-inf/D	t_½	Clearance	V_z
	((ng/mL)/(mg/d))	(h)	((ng/mL*h)/(mg/d))	(h)	(L/h)	(L)
No. of Samples	86	86	66	79	79	79
Mean	1.70 ± 1.18	2.07 ± 1.37	5.49 ± 2.75	1.98 ± 0.96	235 ± 149	644 ± 460

PK parameters (± SD). Means of all ages and dose levels
C_max/D, maximum concentration normalized to 1 mg vorinostat per day; T_max, time at maximum concentration; AUC0_inf/D, area under the curve from 0 to infinitive normalized to 1 mg vorinostat per day; t_½, half-life time of vorinostat; V_z, distribution volume

ISSN: 1868-7083